ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021
Less Is More-Ways to Move Forward for Improved Breast Cancer Risk Stratification.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Evaluating mammographic density polygenic risk score for contralateral breast cancer risk prediction.Scientific reports · 2026Article
- Epidemiology and Risk Factors for Breast Cancer: 21st Century Advances, Gaps to Address through Interdisciplinary Science.Cold Spring Harbor perspectives in medicine · 2023Review
- Variability Among Breast Cancer Risk Classification Models When Applied at the Level of the Individual Woman.Journal of general internal medicine · 2023Article
- BREAst screening Tailored for HEr (BREATHE)-A study protocol on personalised risk-based breast cancer screening programme.PloS one · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer risk models increasingly are including mammographic density (MD) and polygenic risk scores (PRS) to improve identification of higher-risk women who may benefit from genetic screening, earlier and supplemental breast screening, chemoprevention, and other targeted interventions. Here, we present additional considerations for improved clinical use of risk prediction models with MD, PRS, and questionnaire-based risk factors. These considerations include whether changing risk factor patterns, including MD, can improve risk prediction and management, and whether PRS could help inform breast cancer screening without MD measures and prior to the age at initiation of population-based mammography. We further argue that it may be time to reconsider issues around breast cancer risk models that may warrant a more comprehensive head-to-head comparison with other methods for risk factor assessment and risk prediction, including emerging artificial intelligence methods. With the increasing recognition of limitations of any single mathematical model, no matter how simplified, we are at an important juncture for consideration of these different approaches for improved risk stratification in geographically and ethnically diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.